Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study
Table 5
Subgroup analysis between intermediate- (100 mCi) and high-dose (150 mCi) groups according to the ATA risk stratification after propensity score matching.
Intermediate-risk
100 mCi (n = 184)
150 mCi (n = 186)
value
Age (years)
45.4 ± 14.1 (range, 20–65)
45.3 ± 13.3 (range, 16–80)
0.986
Female
135 (73.4%)
141 (75.8%)
0.643
Tumor size (cm)
1.4 ± 0.9
1.4 ± 0.9
0.739
T stage
0.840
T1/T2/T3a/T3b/T4
157 (85.2%)/23 (12.5%)/1 (0.6%)/2 (1.1%)/1 (0.6%)
162 (87.1%)/22 (11.8%)/1 (0.5%)/1 (0.5%)/0
N stage
0.577
N0/N1a/N1b
37 (20.1%)/101 (54.9%)/46 (25.0%)
32 (17.2%)/112 (60.2%)/42 (22.6%)
Pre-op. serum Tg (ng/mL)
44.3 ± 113.1
41.2 ± 96.6
0.774
Post-RAI serum Tg (ng/mL)
5.3 ± 14.5
7.7 ± 17.3
0.137
Recurrence
11 (6.0%)
11 (5.9%)
0.979
High-risk
100 mCi (n = 45)
150 mCi (n = 39)
value
Age (years)
47.6 ± 11.7 (range, 12–78)
50.2 ± 12.4 (range, 14–84)
0.338
Female
37 (72.9%)
37 (78.5%)
0.097
Tumor size (cm)
1.6 ± 0.8
1.4 ± 0.6
0.068
T stage
0.213
T1/T2/T3a/T3b/T4
0/0/0/45 (100%)/0
0/0/0/37 (94.9%)/2 (5.1%)
N stage
0.114
N0/N1a/N1b
4 (8.9%)/23 (51.1%)/18 (40%)
10 (25.6%)/15 (38.5%)/14 (35.9%)
Pre-op. serum Tg (ng/mL)
23.6 ± 31.0
53.3 ± 118.7
0.109
Post-RAI serum Tg (ng/mL)
4.3 ± 10.0
3.4 ± 5.9
0.612
Recurrence
2 (4.4%)
1 (2.6%)
0.643
Data are expressed as the patient’s number (%) or mean ± SD. A statistically significant difference was defined as . Abbreviation: ATA, American thyroid association; T, tumor; N, node; pre-op, preoperative; post-RAI, after radioactive iodine therapy; Tg, thyroglobulin.
